PhecdaMed

CompanyChina

PhecdaMed develops one asset, in phase 2 (TJ0113 in Parkinson's disease). Mostly small molecule acting on autophagy; based in China.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1
  • TJ0113

    Selective mitophagy activator

    Phase 2, Small molecule, Autophagy, Parkinson's disease, sarcopenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies6

Intelligence